Tumor-Associated Antigen-MHC Complex (TAA-MHC)

The tumor-associated antigen-MHC complex is a crucial molecular assembly formed when a peptide derived from a tumor-associated antigen (TAA) is bound and presented by a major histocompatibility complex (MHC) molecule on the surface of cells. This complex enables T cells to recognize and respond to malignant cells. It is a key target for cancer immunotherapy, influencing both prognosis and therapeutic response. Tumors often develop mechanisms to evade immune detection by altering the expression or function of components involved in TAA-MHC presentation. The TAA-MHC complex can be either Class I or Class II, recognized by CD8+ and CD4+ T-cells, respectively.

Other names

Tumor antigen-MHC complexTAA-MHC Class ITAA-MHC Class IITumor-derived peptide-MHC complex

Checkpoint inhibitors enhance T-cell recognition of TAA-MHC; Therapeutic vaccines increase the presentation of TAA-MHC; CAR-T cells redirect T-cells to recognize TAA-MHC.